# Zimmer Biomet (ZBH) Q2 2026 earnings

Results filed 2026-08-05 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/zbh/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/1136869/000119312526333761/0001193125-26-333761-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Zimmer Biomet cleared its next-generation ROSA Shoulder System and raised full-year guidance as go-to-market changes and its innovation cycle gain traction.

Zimmer Biomet received U.S. FDA 510(k) clearance for the next generation ROSA Shoulder System and completed first cases. The company says it is the first in the industry to support both glenoid and humeral bone preparation for anatomic and reverse techniques. Technology & Data, Bone Cement and Surgical sales grew 21.1%, while hips grew 5.0% and knees were flat.
Management is steering toward what CEO Ivan Tornos calls the boldest leader in MedTech, through commercial transformation and its innovation cycle. It is also raising share repurchase expectations to up to $1 billion for 2026. The tension is that knees, the largest category, are barely growing, and the sales network transformation and product rationalization carry execution risk.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Net earnings | $198.3 million |  | GAAP |
| Diluted EPS | $1.03 | up 33.8% | GAAP |
| Adjusted diluted EPS | $2.07 | consistent with the prior year period | non-GAAP |
| Gross margin | 63.3% | vs. 63.8% a year ago | GAAP |
| Operating profit | $326.1 | vs. $300.0 million a year ago | GAAP |
| Operating profit margin | 15.0% | vs. 14.4% a year ago | GAAP |
| Operating cash flow | $447.9 million |  | GAAP |
| Free cash flow | $308.3 million |  | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| United States net sales | $1,239.9 | up 5.6% reported; 4.6% organic constant currency |
| International net sales | 937.0 | up 3.7% reported; 3.1% organic constant currency |
| Knees | 828.9 | up 0.4% reported; 0.1% constant currency |
| Hips | 562.7 | up 5.0% reported; 5.1% constant currency |
| S.E.T. (Sports Medicine, Extremities, Trauma, CMF, Thoracic) | 586.0 | up 6.4% reported; 3.4% organic constant currency |
| Technology & Data, Bone Cement and Surgical | 199.4 | up 21.1% reported; 21.5% constant currency |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Reported revenue change | year ending December 31, 2026 (reported revenue change) | 3.9% - 4.9% |
| Constant currency revenue change | year ending December 31, 2026 (constant currency revenue change) | 3.4% - 4.4% |
| Organic constant currency revenue change | year ending December 31, 2026 (organic constant currency revenue change) | 2.25% - 3.25% |
| Adjusted diluted EPS | year ending December 31, 2026 | $8.47 - $8.59 |

## Key takeaways

1. **Next-generation ROSA Shoulder System cleared and in first cases** Zimmer Biomet received FDA 510(k) clearance and completed first cases of the system, which supports both glenoid and humeral bone preparation for anatomic and reverse techniques. It extends the ROSA robotics platform into shoulders.
2. **Technology, bone cement and surgical lines grew fastest** The Technology & Data, Bone Cement and Surgical category grew 21.1%, far ahead of other categories. This points to demand for the company's technology-linked offerings.
3. **Knees were nearly flat despite robotics recognition** Knees grew 0.4% reported, with U.S. up 1.4% and International down 0.9%. ROSA Knee with OptimiZe won a 2026 MedTech Breakthrough Award, but the largest category is not yet showing growth.
4. **Hips grew 5.0%, led by the United States** U.S. hips grew 5.9% and international hips 4.0%. Hips are a steady contributor alongside the technology-linked categories.
5. **Guidance raised on go-to-market progress and innovation** Management raised full-year revenue and adjusted EPS guidance, citing a strong first half, healthy underlying markets, go-to-market changes progressing as planned and momentum from its innovation cycle. It also raised its 2026 buyback expectation to up to $1 billion.

## Questions

**What did Zimmer Biomet launch this quarter?** It received FDA 510(k) clearance for the next generation ROSA Shoulder System and completed first cases. The company describes it as the first in the industry to support both glenoid and humeral bone preparation for anatomic and reverse techniques.
**Which product categories drove growth?** Technology & Data, Bone Cement and Surgical grew 21.1% and hips grew 5.0%. Knees grew only 0.4% reported.
**What is management's strategic message?** CEO Ivan Tornos said go-to-market changes are progressing as planned and the innovation cycle has momentum. He said the company aims to build the boldest leader in MedTech and deliver consistent, durable growth.
**How is the company using its capital?** It raised its 2026 share repurchase expectation to up to $1 billion. It repurchased $500.8 million of common stock in the first six months.
**Is there any leadership change in the quarter?** Chintan Desai was named president of the Asia Pacific Region, replacing Sang Yi, who departs on Aug. 28.

